Market Overview

Leerink Swann Upgrades MedAssets To Outperform

Related MDAS
Mercy Medical Center Selects MedAssets for Supply Chain Management and Performance Improvement Solutions
Benzinga's Top Downgrades

Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform.

The target price for MedAssets is set to $26.

MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.

MedAssets' shares rose 0.28% to close at $21.25 yesterday.

Latest Ratings for MDAS

Jan 2016SunTrust Robinson HumphreyTerminatesNeutral
Nov 2015JP MorganAssumesNeutral
Nov 2015JefferiesDowngradesBuyHold

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Leerink SwannUpgrades Analyst Ratings


Related Articles (MDAS)

View Comments and Join the Discussion!

Partner Center